Investors Target PROCEPT BioRobotics Over Alleged Sales Inflation
A securities class action lawsuit has been filed against PROCEPT BioRobotics, accusing the company of artificially inflating revenues through aggressive bulk-discount programs. Shareholders who acquired common stock between February 28, 2024, and February 25, 2026, face a September 22, 2026, deadline to seek lead plaintiff status in the ongoing litigation.
By Money Talk·September 7, 2026·2 min read·710 reads
The complaint, spearheaded by the firm Hagens Berman Sobol Shapiro LLP, centers on allegations that PROCEPT misled investors regarding its handpiece sales for the Aquablation therapy system. According to the filing, the company allegedly incentivized customers to purchase bulk orders that exceeded actual procedure demands. This practice effectively pulled future sales into current periods, creating a facade of growth while masking significant excess inventory in the field.
The discrepancy began to surface in August 2025, when the company reported quarterly results that missed analyst expectations. Subsequent disclosures throughout late 2025 and early 2026 revealed that U.S. handpiece sales had consistently outpaced actual procedures since early 2023. By the time PROCEPT disclosed in February 2026 that cumulative excess inventory had reached 10,000 units and eliminated its bulk discount program, the company's share price had dropped by more than 48% from its August 2025 levels.
Reed Kathrein, the Hagens Berman partner leading the investigation, stated that the firm is scrutinizing whether management intentionally concealed these sales practices to meet market expectations. The lawsuit seeks to hold the company accountable for potential violations of federal securities laws during the specified class period.
Comments (0)
No comments yet. Be the first!